Dana Farber Cancer Institute/Mass General Hospital — Boston, Massachusetts

Dana Farber Cancer Institute/Mass General Hospital is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 48/100 (POOR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute/Mass General Hospital has participated in 1 clinical trials.

Therapeutic areas: Synovial Sarcoma, Cancer, Soft Tissue Sarcoma.

Sponsors: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Sponsor Feasibility Report

Trust Score: 48/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute/Mass General Hospital?

Dana Farber Cancer Institute/Mass General Hospital has a Crixeo Trust Score of 48/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute/Mass General Hospital conducted?

Dana Farber Cancer Institute/Mass General Hospital has 1 clinical trials on record. Their work covers Synovial Sarcoma, Cancer, Soft Tissue Sarcoma.

Is Dana Farber Cancer Institute/Mass General Hospital accredited by Crixeo Health?

Dana Farber Cancer Institute/Mass General Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute/Mass General Hospital?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.